Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 242

1.

Kynurenine and its metabolites in Alzheimer's disease patients.

Gulaj E, Pawlak K, Bien B, Pawlak D.

Adv Med Sci. 2010;55(2):204-11. doi: 10.2478/v10039-010-0023-6.

PMID:
20639188
2.

Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls.

Schwarz MJ, Guillemin GJ, Teipel SJ, Buerger K, Hampel H.

Eur Arch Psychiatry Clin Neurosci. 2013 Jun;263(4):345-52. doi: 10.1007/s00406-012-0384-x. Epub 2012 Nov 29.

PMID:
23192697
3.

Increased breakdown of kynurenine towards its neurotoxic branch in bipolar disorder.

Birner A, Platzer M, Bengesser SA, Dalkner N, Fellendorf FT, Queissner R, Pilz R, Rauch P, Maget A, Hamm C, Herzog-Eberhard S, Mangge H, Fuchs D, Moll N, Zelzer S, Schütze G, Schwarz M, Reininghaus B, Kapfhammer HP, Reininghaus EZ.

PLoS One. 2017 Feb 27;12(2):e0172699. doi: 10.1371/journal.pone.0172699. eCollection 2017.

4.

Altered serum levels of kynurenine metabolites in patients affected by cluster headache.

Curto M, Lionetto L, Negro A, Capi M, Perugino F, Fazio F, Giamberardino MA, Simmaco M, Nicoletti F, Martelletti P.

J Headache Pain. 2015;17:27. doi: 10.1186/s10194-016-0620-2. Epub 2016 Mar 22.

5.

Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.

Yan EB, Frugier T, Lim CK, Heng B, Sundaram G, Tan M, Rosenfeld JV, Walker DW, Guillemin GJ, Morganti-Kossmann MC.

J Neuroinflammation. 2015 May 30;12:110. doi: 10.1186/s12974-015-0328-2.

6.

Involvement of the kynurenine pathway in human glioma pathophysiology.

Adams S, Teo C, McDonald KL, Zinger A, Bustamante S, Lim CK, Sundaram G, Braidy N, Brew BJ, Guillemin GJ.

PLoS One. 2014 Nov 21;9(11):e112945. doi: 10.1371/journal.pone.0112945. eCollection 2014.

7.

Altered kynurenine pathway metabolites in serum of chronic migraine patients.

Curto M, Lionetto L, Negro A, Capi M, Fazio F, Giamberardino MA, Simmaco M, Nicoletti F, Martelletti P.

J Headache Pain. 2015;17:47. doi: 10.1186/s10194-016-0638-5. Epub 2016 Apr 29.

8.

Kynurenine Pathway Metabolites in Alzheimer's Disease.

Giil LM, Midttun Ø, Refsum H, Ulvik A, Advani R, Smith AD, Ueland PM.

J Alzheimers Dis. 2017;60(2):495-504. doi: 10.3233/JAD-170485.

PMID:
28869479
9.

Tryptophan metabolism via the kynurenine pathway in experimental chronic renal failure.

Pawlak D, Tankiewicz A, Mysliwiec P, Buczko W.

Nephron. 2002 Mar;90(3):328-35.

PMID:
11867954
10.

A single-run liquid chromatography mass spectrometry method to quantify neuroactive kynurenine pathway metabolites in rat plasma.

Orsatti L, Speziale R, Orsale MV, Caretti F, Veneziano M, Zini M, Monteagudo E, Lyons K, Beconi M, Chan K, Herbst T, Toledo-Sherman L, Munoz-Sanjuan I, Bonelli F, Dominguez C.

J Pharm Biomed Anal. 2015 Mar 25;107:426-31. doi: 10.1016/j.jpba.2015.01.030. Epub 2015 Jan 24.

PMID:
25668794
11.

Development and validation of a single analytical method for the determination of tryptophan, and its kynurenine metabolites in rat plasma.

Möller M, Du Preez JL, Harvey BH.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jun 1;898:121-9. doi: 10.1016/j.jchromb.2012.04.030. Epub 2012 May 4.

PMID:
22608808
12.

The impact of electroconvulsive therapy on the tryptophan-kynurenine metabolic pathway.

Guloksuz S, Arts B, Walter S, Drukker M, Rodriguez L, Myint AM, Schwarz MJ, Ponds R, van Os J, Kenis G, Rutten BP.

Brain Behav Immun. 2015 Aug;48:48-52. doi: 10.1016/j.bbi.2015.02.029. Epub 2015 Mar 9.

PMID:
25765557
13.

Kynurenine pathway metabolites in cerebrospinal fluid and serum in complex partial seizures.

Heyes MP, Saito K, Devinsky O, Nadi NS.

Epilepsia. 1994 Mar-Apr;35(2):251-7.

PMID:
8156942
14.

Kynurenine metabolism in Alzheimer's disease.

Baran H, Jellinger K, Deecke L.

J Neural Transm (Vienna). 1999;106(2):165-81.

PMID:
10226937
15.

Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.

Meier TB, Drevets WC, Wurfel BE, Ford BN, Morris HM, Victor TA, Bodurka J, Teague TK, Dantzer R, Savitz J.

Brain Behav Immun. 2016 Mar;53:39-48. doi: 10.1016/j.bbi.2015.11.003. Epub 2015 Nov 4.

16.

Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms.

Schefold JC, Zeden JP, Fotopoulou C, von Haehling S, Pschowski R, Hasper D, Volk HD, Schuett C, Reinke P.

Nephrol Dial Transplant. 2009 Jun;24(6):1901-8. doi: 10.1093/ndt/gfn739. Epub 2009 Jan 20.

PMID:
19155537
17.

Kynurenic acid and 3-hydroxykynurenine production from D-kynurenine in mice.

Wang XD, Notarangelo FM, Wang JZ, Schwarcz R.

Brain Res. 2012 May 21;1455:1-9. doi: 10.1016/j.brainres.2012.03.026. Epub 2012 Mar 17.

18.

Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia.

Notarangelo FM, Wilson EH, Horning KJ, Thomas MA, Harris TH, Fang Q, Hunter CA, Schwarcz R.

Schizophr Res. 2014 Jan;152(1):261-7. doi: 10.1016/j.schres.2013.11.011. Epub 2013 Dec 15.

19.
20.

LC-MS/MS-based quantification of kynurenine metabolites, tryptophan, monoamines and neopterin in plasma, cerebrospinal fluid and brain.

Fuertig R, Ceci A, Camus SM, Bezard E, Luippold AH, Hengerer B.

Bioanalysis. 2016 Sep;8(18):1903-17. doi: 10.4155/bio-2016-0111. Epub 2016 Aug 15.

Supplemental Content

Support Center